source · application/json
source_9458af7926e94e72
sha256 2986dfa8f6ef8a8d5772cd8dca18b7eda005877a6ff991ca5d719c7f9a889ab0
by researka:v2 · 2026-05-28 23:51:00.110932+04:00
{"publication_id": "b8dee5f7-0023-4af5-bacc-446de915555a", "traces": [{"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "What does the current evidence establish about Coenzyme Q10 Ubiquinol and human geroscience? This synthesis tests the thesis that evidence for Coenzyme Q10 ubiquinol is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. This paper synthesizes coenzyme q10 ubiquinol as an aging-related intervention across 63 included source papers and 3843 high-confidence extracted claims. The evidence profile contains 7 direct clinical sources, 24 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 283 cross-study disagreements across the evidence base. Positive study-level signals concentrate in longevity, contextual adjacent evidence, mortality and survival, null signals in dosing and pharmacokinetics, contextual adjacent evidence, safety and comorbidity, and negative signals in cardiometabolic. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect. The conclusion is that coenzyme q10 ubiquinol remains a bounded geroscience case: mechanistic plausibility and selected clinical signals justify further targeted testing, while mixed and null findings limit any unqualified anti-aging claim. This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, immune, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "| Contextual Adjacent Evidence | n=15; claims=999 | null signal in 8/15 sources | 7 indirect; 8 review | limited corpus depth in this outcome class |", "claim_id": "claim_7"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "| Dosing and Pharmacokinetics | n=13; claims=793 | null signal in 10/13 sources | 1 direct; 7 indirect; 5 review | limited corpus depth in this outcome class |", "claim_id": "claim_8"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "| Safety and Comorbidity | n=3; claims=273 | null signal in 2/3 sources | 1 indirect; 2 review | limited corpus depth in this outcome class |", "claim_id": "claim_9"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Quantitative synthesis from Zhang (2026) provides pooled effect estimates supporting CoQ10 efficacy in metabolic disorders. Specifically, CoQ10 significantly reduced hemoglobin A1c by a weighted mean difference (WMD) of -0.22% (95% CI: -0.37, -0.06; P = 0.006) and fasting glucose by WMD = -10.07 mg/dL. Additional meta-analytic outcomes achieved conventional significance at P = 0.001, P = 0.003, and P = 0.013. By contrast, Spiegeleer (2025) observed that statin use in older adults was associated with a lower gait speed reserve (GSR) compared to non-use (-1.9 cm/s [95% CI, -3.1 to -0.72]), yielding P < 0.001 for the primary comparison and additional p-values of 0.002, 0.024, 0.034, and 0.267 for secondary analyses.", "claim_id": "claim_10"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Mechanistically, CoQ10's role as a mitochondrial electron carrier and lipid-soluble antioxidant provides a plausible substrate for cardiometabolic benefit. Zhang (2026) documented significant reductions in inflammatory markers alongside glycemic improvements, consistent with mechanistic pathways linking mitochondrial dysfunction to insulin resistance and chronic inflammation. Preclinical data cited within this systematic review support CoQ10-mediated improvements in endothelial function and oxidative stress buffering. The RCT by Donnino (2015) extends this mechanistic framework to critical illness, where mitochondrial bioenergetic failure is a hallmark of septic shock.", "claim_id": "claim_11"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "The evidence base for CoQ10 dosing and pharmacokinetic parameters spans diverse clinical contexts and populations. This same trial reported significant reductions in oxidative stress markers, as plasma isofuran concentrations decreased (P = 0.003). Dosing in mechanistic trials has commonly been 100-300 mg per day, as exemplified by the 300 mg/day regimen used in burn patients in Kiani 2024.", "claim_id": "claim_12"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Mechanistically, CoQ10's role in mitochondrial electron transport provides a plausible substrate for its observed effects on oxidative stress and inflammation. Preclinical and human mechanistic data suggest CoQ10 may mitigate lipid peroxidation, as indicated by the reduction in isofuran concentrations (P = 0.003) noted in the hemodialysis cohort (Yeung 2015). The mechanistic substrate underlying the anti-inflammatory findings in the multiple sclerosis trial (Moccia 2019) may involve CoQ10's attenuation of interferon-β1a-induced peripheral oxidative stress.", "claim_id": "claim_13"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "A notable tension within the corpus concerns the consistency of oxidative stress outcomes across clinical populations. While Yeung 2015 and Moccia 2019 reported significant reductions in oxidative and inflammatory markers, the clinical RCT in burn patients (Kiani 2024) found no significant effect on its primary malondialdehyde endpoint (P = 0.550). Similarly, Greenlee 2025 observed no clinically concerning pharmacokinetic interference between CoQ10 and doxorubicin, supporting a favorable safety profile in oncology. The disagreement between the clear positive oxidative findings in some cohorts and the null primary result in the burn patient trial may reflect differences in baseline oxidative burden, disease pathology, or the specific biomarker endpoints chosen across studies.", "claim_id": "claim_14"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "The evidence base for coenzyme Q10 (CoQ10) supplementation and immune/inflammatory outcomes spans multiple study designs, including clinical RCTs in specific patient populations, observational cohorts, and several systematic reviews and meta-analyses. In a randomized, placebo-controlled trial in hepatocellular carcinoma patients after surgery, Liu 2016 investigated CoQ10 supplementation's effects on oxidative stress and inflammation, with mixed results across multiple measured endpoints. The umbrella meta-analysis by Varnousfaderani 2023 synthesized data across studies to evaluate CoQ10's effects on biomarkers of inflammation and oxidative stress in adults. Additional systematic reviews by Zhai 2017, Jorat 2019, Alimohammadi 2021, and Xu 2022 examined various inflammatory markers in coronary artery disease, breast cancer, and chronic kidney disease populations.", "claim_id": "claim_15"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Mechanistically, CoQ10's anti-inflammatory effects are plausibly linked to its role in mitochondrial electron transport and as a lipid-soluble antioxidant, which may reduce oxidative stress-driven NF-κB activation and downstream cytokine production. Jorat 2019's meta-analysis in coronary artery disease patients demonstrated pooled reductions in inflammatory and oxidative stress biomarkers with P < 0.001, P < 0.001, P = 0.001, and P < 0.001 across different markers, supporting a mechanistic link between CoQ10 repletion and reduced inflammation in cardiovascular contexts. Mojaver 2025 reported a dose of 600 mg/day.", "claim_id": "claim_16"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Within the corpus, notable tensions exist regarding the magnitude and consistency of CoQ10's anti-inflammatory effects across different study contexts. The Zhai 2017 systematic review reported unclear overall direction of effect on inflammatory markers, while Jorat 2019 in coronary artery disease found consistent significant reductions across multiple biomarkers. Furthermore, Alehagen 2022b's analysis of a selenium and CoQ10 intervention trial reported null findings for certain immune-related biomarkers (P < 0.001 for some endpoints but with a reported null overall effect direction), creating tension with the positive signal from Dahri 2019. The retracted PCOS study by Rahmani 2018 reported improvements in gene expression related to inflammation, adding further heterogeneity to the evidence base.", "claim_id": "claim_17"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "The evidence base for coenzyme Q10 (CoQ10) and longevity comprises meta-analytic syntheses, long-term RCT follow-ups, and observational cohorts. These converging review-level estimates indicate a consistent, statistically significant survival benefit in cardiac populations.", "claim_id": "claim_18"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "The most sustained clinical support comes from the Alehagen RCT program, which randomized elderly Swedish citizens to selenium (200 µg) plus CoQ10 (200 mg) or placebo for four years. At the 10-year follow-up, cardiovascular mortality was significantly lower in the active arm (Alehagen 2015: P = 0.0003 for CV mortality). A 12-year post-hoc follow-up confirmed the durability of this effect, with the supplementation group showing persistently reduced cardiovascular mortality (Alehagen 2018: P = 0.001). These data represent the strongest direct clinical RCT evidence for a CoQ10-related longevity benefit.", "claim_id": "claim_19"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Mechanistically, CoQ10’s role in mitochondrial electron transport and its capacity to scavenge reactive oxygen species provide a plausible substrate for reduced cardiovascular and all-cause mortality. Preclinical data and human mechanistic studies suggest that CoQ10 supplementation restores mitochondrial membrane potential and reduces lipid peroxidation, effects that are expected to attenuate age-related cardiac decline. The Alehagen program’s biomarker findings—improved selenium-dependent glutathione peroxidase activity and reduced circulating oxidative stress markers—are consistent with this pathway (Alehagen 2016; Alehagen 2015). Philippou 2025 further contextualizes the anti-aging rationale by noting CoQ10’s capacity to mitigate statin-associated mitochondrial dysfunction, which may have downstream effects on sepsis and systemic inflammation outcomes.", "claim_id": "claim_20"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "By contrast, not all evidence converges on a protective signal. These sources introduce heterogeneity into the longevity evidence base, though their relevance to direct CoQ10 supplementation effects is limited by their focus on statin pharmacology rather than exogenous CoQ10.", "claim_id": "claim_21"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Mechanistically, the link between CoQ10/ubiquinol and mortality is theorized to operate through cardiovascular protection and antioxidant pathways, as discussed in the comparative review by Fladerer 2023. This suggests a potential protective signal in acute illness contexts. The underlying premise connecting these statin studies to CoQ10 ubiquinol research rests on the pharmacological interaction of statins with the mevalonate pathway, which suppresses CoQ10 synthesis (Fladerer 2023).", "claim_id": "claim_22"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "A notable tension exists within the corpus between studies reporting null effects and those suggesting benefit. By contrast, Bergqvist 2021 and Papagiannakis 2025 are in agreement on the null effect of statin use on mortality in their respective contexts. This heterogeneity highlights a critical limitation: the evidence base is dominated by indirect studies of statins, a drug class known to affect CoQ10 levels, rather than direct trials of CoQ10 or ubiquinol supplementation. European patients were followed with endpoints including major adverse cardiac events and measures of functional capacity.", "claim_id": "claim_23"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Tensions within this outcome class reflect heterogeneity in study populations, interventions, and endpoints. Spiegeleer (2025) reports a negative cardiometabolic association in older adults, whereas Zhang (2026) documents positive pooled effects on glycemic and lipid parameters across metabolic disorder populations. Zhang (2018) presents a mixed profile with some significant lipid improvements but an unclear overall effect direction, contrasting with the uniformly positive summary estimates in Zhang (2026). Several sources are systematic reviews and meta-analyses examining outcomes in populations where statin use is a key variable, such as heart failure and aortic aneurysm (Bielecka-Dabrowa 2019, Liao 2019). Other studies directly investigate CoQ10 or ubiquinol in clinical or mechanistic contexts, including a randomized controlled trial on ovarian response in women with decreased ovarian reserve (Xu 2018) and a sub-analysis of a double-blind placebo-controlled trial on selenium and CoQ10 in elderly individuals (Alehagen 2023). The corpus also includes systematic reviews on fertility in ovarian aging (Shang 2024), dietary strategies in heart failure (Yu 2024), and the comparative bioavailability of CoQ10 formulations in healthy elderly individuals (Pravst 2020). These studies collectively provide evidence on diverse endpoints, from mortality and metabolic profiles to reproductive and inflammatory outcomes.", "claim_id": "claim_24"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Quantitative findings across these studies reveal a mixture of significant and null results. In the fertility domain, a subgroup analysis indicated an optimal CoQ10 regimen of 30 mg/d for 3 months, though specific p-values for this finding were reported alongside others ranging from P = 0.74 to P < 0.0001 (Shang 2024).", "claim_id": "claim_25"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Mechanistically, the evidence relates to pathways of mitochondrial energy metabolism, antioxidant defense, and inflammation. The clinical RCT by Xu 2018 suggests CoQ10 may improve ovarian response and embryo quality, potentially through enhancing mitochondrial function in oocytes. Preclinical and human data from Alehagen 2019 and Alehagen 2023 indicate that selenium and CoQ10 intervention can alter metabolic profiles and age-related biomarkers, supporting a role in mitigating oxidative stress and inflammation. In exercise physiology, a clinical study found that ubiquinol supplementation at 200 mg affected hematological and inflammatory signaling (Diaz-Castro 2020). By contrast, the large meta-analytic findings on statins (Bielecka-Dabrowa 2019, Symvoulidis 2023) are more indirectly related, as they reflect outcomes in patients on HMG-CoA reductase inhibitors, which can deplete endogenous CoQ10 synthesis, creating a mechanistic rationale for considering CoQ10 status.", "claim_id": "claim_26"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "The corpus presents several within-corpus tensions regarding effect directions and significance. For instance, Bielecka-Dabrowa 2019 reports a strong positive association between statin use and reduced mortality in heart failure, while Symvoulidis 2023 finds a non-significant reduction in bladder cancer risk with statin use. Similarly, Shang 2024 presents unclear or mixed effects of CoQ10 on fertility outcomes, which contrasts with the more definitive changes in aging biomarkers reported in Alehagen 2023. Studies investigating direct CoQ10 supplementation, such as Pravst 2020 on bioavailability and Diaz-Castro 2020 on exercise, report significant effects on pharmacokinetic or physiological markers (P < 0.05), while some broader reviews note null findings for clinical endpoints (Yu 2024). These disagreements highlight the context-dependency of CoQ10's effects and the influence of study design, population, and specific endpoints on observed outcomes.", "claim_id": "claim_27"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Contextual Adjacent Evidence is retained as a separate Results slice (n=15; null signal in 8/15 sources; 7 indirect; no direct clinical anchor) and is not pooled into adjacent endpoint classes.", "claim_id": "claim_28"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "In the Q-SYMBIO sub-group analysis, CoQ10 supplementation demonstrated significant effects on several clinical endpoints. Mortensen 2019 reported statistically significant differences for multiple measures, including endpoints with P = 0.03, P = 0.03, and P < 0.001. These quantitative findings are detailed in Table 2 (Per-Study Endpoint Evidence).", "claim_id": "claim_29"}, {"candidate_sources": [{"doi": "10.1186/s12872-024-04232-z", "study": "Xu 2024", "url": "https://doi.org/10.1186/s12872-024-04232-z"}, {"doi": "10.1007/s11357-025-01682-x", "study": "Spiegeleer 2025", "url": "https://doi.org/10.1007/s11357-025-01682-x"}, {"doi": "10.1016/j.advnut.2024.100273", "study": "Shang 2024", "url": "https://doi.org/10.1016/j.advnut.2024.100273"}, {"doi": "10.3390/nu12123780", "study": "Alehagen 2020", "url": "https://doi.org/10.3390/nu12123780"}, {"doi": "10.1371/journal.pone.0232636", "study": "Phan 2020", "url": "https://doi.org/10.1371/journal.pone.0232636"}], "claim": "Mechanistically, the safety and comorbidity outcomes observed in these trials relate to oxidative stress modulation and mitochondrial function. Preclinical data and mechanistic human studies suggest CoQ10 serves as a critical electron carrier in the mitochondrial respiratory chain, and supplementation may ameliorate myocardial energetics in heart failure. The clinical RCT evidence from Mortensen 2019 provides direct human data supporting this mechanistic pathway in a cardiovascular disease population, bridging the gap between bench observations and clinical outcomes.", "claim_id": "claim_30"}]}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "b8dee5f7-0023-4af5-bacc-446de915555a",
"researka_submission_id": "d634654e-17d4-4dad-8977-cb586fa6e83d",
"sidecar_name": "citation_traces.json",
"sidecar_url": "https://api.researka.org/publications/b8dee5f7-0023-4af5-bacc-446de915555a/sidecars/citation_traces.json"
}